Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Mild to Moderate COVID-19 Clinical Trial

Official title:

A Phase II/III,Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05675072
• Other study ID #: FB2001-302
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: January 4, 2023
• Est. completion date: December 2023

Study information

• Verified date: January 2023
• Source: Frontier Biotechnologies Inc.
• Contact: Yue Zhang
• Phone: +86 02569760330
• Email: lczhangyue[@]frontierbiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19). A total of about 1336 subjects are planned to be enrolled. The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.

Description:

Coronavirus Disease 2019 (COVID -19) is a respiratory illness that can spread from person to person. The infectious agent that causes COVID -19 is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), was first identified during a recent outbreak in December 2019, Patients with COVID-19 have symptoms of fever, cough, and shortness of breath along with non-specific symptoms including myalgia and fatigue.

FB2001 is a small-molecule inhibitor of coronavirus 3CL protease(3CLpro). In phase I clinical trial, FB2001 for Inhalation were safe and tolerable well in healthy subjects, and were projected to be effective in patients according to its pharmacokinetic profile.

This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019 (COVID-19). The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1336
• Est. completion date: December 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years, male or female;

• Confirmed SARS-CoV-2 infection as determined by Reverse Transcription - Polymerase Chain Reaction(RT -PCR) in any specimen collected within 5 days prior to randomization.

Note: RT-PCR is the preferred method; however, with evolving approaches to laboratory confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral RNA or protein are allowed if authorized for use in the country;

• Patients with mild or moderate COVID-19.

• Initial onset of signs/symptoms attributable to COVID -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to COVID -19 present on the day of randomization;

• Women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose;

• Patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.

Exclusion Criteria:

• Patients who are currently or are expected to potentially progress to severe/critical COVID-19 within 48 h of randomization;

• Patients with chronic respiratory diseases, including bronchial asthma and chronic obstructive pulmonary disease etc.

• Known history of moderate-severe liver impairment (e.g., Child-Pugh grade B or C, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 5x upper limit normal (ULN) , or acute liver failure within 6 months prior to screening;.

• Known history of severe renal impairment (e.g., Chronic Kidney Disease-Improved Prediction Equations(CKD-EPI)formula based on serum creatinine, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2), or was receiving renal replacement therapy, such as peritoneal dialysis or hemodialysis, within 6 months prior to screening;

• Impaired immune system (including patients treated with systemic corticosteroids or other immunosuppressive agents, or cancer progression or recurrence)

• Suspected or confirmed concurrent active systemic infections other than COVID-19 that may interfere with the assessment of response to study interventions.

• Need for radiotherapy, chemotherapy, emergency surgery or surgical treatment at screening, or other emergencies (e.g. acute coronary syndrome, acute pulmonary embolism, etc.).

• Patients with a history of cardiopulmonary resuscitation or major surgery within 30 days prior to randomization, and patients with other potentially life-threatening clinical conditions or other emergencies.

• History of hypersensitivity or other contraindications to any component of the study intervention.

• Patients who received or expected to receive anti-SARS-CoV-2 viral drugs (e.g., nirmatrelvir/ritonavir, molnupiravir, etc.) within 14 days prior to randomization.

• Have received (within 30 days prior to randomization or within 5 half-lives, whichever is longer) or expect to receive COVID-19 monoclonal antibody or recovery COVID-19 plasma therapy.

• Any SARS-CoV-2 vaccination within 3 months prior to randomization.

• Within 28 days or 5 half-lives (whichever is longer) prior to randomization or in clinical studies with other investigational drugs or devices, including studies for COVID-19.

• Mental illnesses that, in the judgment of the investigator, are not appropriate for participation in this study.

• Any other situation that the investigator believes may affect the subject's informed consent or adherence to the protocol, or the subject's participation in the study may affect the outcome of the study or his or her own safety, in the investigator's judgment.

Related Conditions & MeSH terms

• COVID-19
• Mild to Moderate COVID-19

Intervention

Drug:
• FB2001
FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
• FB2001 placebo
FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.

Locations

Country	Name	City	State
China	Shenzhen Third People's Hospital	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Frontier Biotechnologies Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence and severity of Treatment-Emergent Adverse Events(TEAEs)	safety evaluation	Up to Day 29
Other	Incidence of withdrawals due to Adverse Events(AEs)	safety evaluation	Up to Day 29
Other	Incidence of Serious Adverse Events(SAEs)	safety evaluation	Up to Day 29
Other	Safety as determined by abnormality in haematology	Measurement of white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin (Hb), neutrophils absolute count, lymphocytes absolute count, monocytes absolute count, eosinophils absolute count, Platelets absolute count.	Up to Day 29
Other	Safety as determined by abnormality in clinical chemistry	Measurement of sodium, potassium, urea/blood urea nitrogen (BUN), creatinine, albumin, calcium, phosphate, glucose, c-reactive protein (CRP), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), total bilirubin, conjugated bilirubin, creatine kinase.	Up to Day 29
Other	Incidence of treatment-related grade 3 or above TEAEs	safety evaluation	Up to Day 29
Other	Safety as determined by abnormality in urinalysis	Measurement of glucose, protein, blood and microscopy.	Up to Day 29
Other	Safety as determined by abnormality in Coagulation.	Measurement of international normalised ratio (INR), prothrombin time, activated partial thrombin time (aPTT).	Up to Day 29
Other	Incidence of treatment-related adverse events (TRAEs)	safety evaluation	Up to Day 29
Other	Incidence of discontinuation of study treatment due to TEAEs	safety evaluation	Up to Day 29
Other	Incidence of abnormal 12-lead electrocardiogram (ECG)	Results for P wave PR interval, QRS duration, QT interval, QTcF interval, RR interval, and heart rate will be analyzed.	Up to Day 29
Other	Safety as determined by abnormal vital signs (blood pressure, pulse rate, body temperature, and respiratory rate)	Measurement of systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), pulse rate (beats per minute), body temperature (in degree Celsius), respiratory rate (breaths per minute).	Up to Day 29
Primary	Time to sustained recovery of COVID-19-related signs/symptoms	Sustained recovery of a COVID-19-related sign/symptom is defined as a COVID-19-related sign/symptom score of 0 for 3 consecutive days, i.e., disappearance of COVID-19-related symptoms or return to the status prior to the onset of COVID-19.	Up to Day 29
Secondary	Proportion of participants who have progression of COVID-19 .	Disease progression is defined as disease severity from mild to moderate or severe or critical, or moderate to severe or critical, or all-cause death	Up to Day 29
Secondary	Time to sustained alleviation of COVID-19-related sign/symptom.	Sustained alleviation of COVID-19-related signs/symptoms are defined as the COVID-19-related sign/symptom score from 0 or 1 to 0 at baseline or from 2 or 3 to 1 or 0 at baseline for 3 consecutive days.	Up to Day 29
Secondary	Time to sustained recovery of 5 key COVID-19-related sign/symptom	Sustained recovery of a COVID-19-related sign/symptom is defined as a COVID-19-related sign/symptom score of 0 for 3 consecutive days, i.e., disappearance of COVID-19-related symptoms or return to the status prior to the onset of COVID-19.	Up to Day 29
Secondary	Time to sustained alleviation of 5 key COVID-19-related sign/symptom	Sustained alleviation of COVID-19-related signs/symptoms are defined as the COVID-19-related sign/symptom score from 0 or 1 to 0 at baseline or from 2 or 3 to 1 or 0 at baseline for 3 consecutive days.	Up to Day 29
Secondary	Proportion of participants who experience sustained recovery of COVID-19 sign/symptom	no special description	Day 3 to Day 21
Secondary	Proportion of participants who experience sustained alleviation of COVID-19-related sign/symptom	no special description	Day 3 to Day 21
Secondary	Duration of each targeted COVID-19-related sign/symptom.	no special description	Up to Day 29
Secondary	Time to sustained virus clearance of SARS-CoV-2 in nasopharyngeal swabs	no special description	Up to Day 29
Secondary	Changes in SARS-CoV-2 viral load	no special description	Up to Day 29
Secondary	Change in EQ-5D-5L index score	The Euroquol Quality of Life 5-Dimension 5-Level Scale(EQ-5D-5L) index score consists of five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Each dimension has five scales: no difficulty, a little difficulty, moderate difficulty, severe difficulty, and very severe difficulty	Up to Day 29